Eisai Plans More Global Cost Cuts In Wake Of Loss Of Aricept Patent
This article was originally published in PharmAsia News
Eisai says it plans additional cost cuts by the end of the current fiscal year March, 2013, as a result of the patent-expiration of Alzheimer’s disease drug Aricept (donepezil).
You may also be interested in...
A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.
Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.